RBC Capital raised the firm’s price target on ResMed (RMD) to $255 from $247 and keeps a Sector Perform rating on the shares. The company’s Q3 result showed ongoing solid growth in revenue and earnings, and while they were in line with market expectations, a positive update was that the company’s products should continue to be largely exempt from U.S. import tariffs, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- ResMed price target raised to $274 from $269 at KeyBanc
- Resmed’s Strong Q3 Performance and Strategic Positioning Justify Buy Rating
- Resmed Inc. Reports Strong Q3 2025 Earnings
- Closing Bell Movers: Robert Half down 15% after earnings miss